The next-generation Open Targets Platform: reimagined, redesigned, rebuilt

Author:

Ochoa David12ORCID,Hercules Andrew12,Carmona Miguel12,Suveges Daniel12,Baker Jarrod12,Malangone Cinzia12,Lopez Irene12,Miranda Alfredo12,Cruz-Castillo Carlos12,Fumis Luca12,Bernal-Llinares Manuel12ORCID,Tsukanov Kirill12,Cornu Helena12,Tsirigos Konstantinos12,Razuvayevskaya Olesya12,Buniello Annalisa12ORCID,Schwartzentruber Jeremy13,Karim Mohd13,Ariano Bruno13,Martinez Osorio Ricardo Esteban12,Ferrer Javier12,Ge Xiangyu13,Machlitt-Northen Sandra4,Gonzalez-Uriarte Asier12,Saha Shyamasree2,Tirunagari Santosh2,Mehta Chintan12,Roldán-Romero Juan María12,Horswell Stuart13,Young Sarah13,Ghoussaini Maya13,Hulcoop David G14,Dunham Ian123ORCID,McDonagh Ellen M12ORCID

Affiliation:

1. Open Targets, Wellcome Genome Campus , Hinxton, Cambridgeshire CB10 1SD, UK

2. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI) , Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK

3. Wellcome Sanger Institute , Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK

4. GlaxoSmithKline plc, GSK Medicines Research Centre , Gunnels Wood Road, Stevenage, SG1 2NY, UK

Abstract

AbstractThe Open Targets Platform (https://platform.opentargets.org/) is an open source resource to systematically assist drug target identification and prioritisation using publicly available data. Since our last update, we have reimagined, redesigned, and rebuilt the Platform in order to streamline data integration and harmonisation, expand the ways in which users can explore the data, and improve the user experience. The gene–disease causal evidence has been enhanced and expanded to better capture disease causality across rare, common, and somatic diseases. For target and drug annotations, we have incorporated new features that help assess target safety and tractability, including genetic constraint, PROTACtability assessments, and AlphaFold structure predictions. We have also introduced new machine learning applications for knowledge extraction from the published literature, clinical trial information, and drug labels. The new technologies and frameworks introduced since the last update will ease the introduction of new features and the creation of separate instances of the Platform adapted to user requirements. Our new Community forum, expanded training materials, and outreach programme support our users in a range of use cases.

Funder

Wellcome Trust

Open Targets

Publisher

Oxford University Press (OUP)

Subject

Genetics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3